Quarterly report pursuant to Section 13 or 15(d)

Schedule of Earnings Per Share (Details)

v3.24.3
Schedule of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023
(Loss) income per common share from continuing operations                
(Loss) income from continuing operations, net of taxes $ (8,806,000) [1]     $ 246,000     $ (16,049,000) [1] $ 448,000
Basic (loss) income per share $ (0.56)     $ 0.02     $ (1.09) $ 0.03
Diluted (loss) income per share $ (0.56)     $ 0.02     $ (1.09) $ 0.03
(Loss) income per common share from discontinued operations, net of taxes                
(Loss) income from discontinued operations, net of taxes $ (173,000)     $ 95,000     $ (441,000) $ (44,000)
Basic (loss) income per share $ (0.01)     $ 0.01     $ (0.03)
Diluted loss per share $ (0.01)         $ (0.03)
Net (loss) income per common share                
Net (loss) income $ (8,979,000) $ (3,951,000) $ (3,560,000) $ 341,000 $ 474,000 $ (411,000) $ (16,490,000) $ 404,000
Basic (loss) income per share $ (0.57)     $ 0.03     $ (1.12) $ 0.03
Diluted (loss) income per share $ (0.57)     $ 0.02     $ (1.12) $ 0.03
Weighted average shares outstanding:                
Basic weighted average shares outstanding 15,803     13,568     14,695 13,468
Add: dilutive effect of stock options     370     244
Add: dilutive effect of warrants     41     37
Diluted weighted average shares outstanding 15,803     13,979     14,695 13,749
Stock Options [Member]                
Potential shares excluded from above weighted average share calculations due to their anti-dilutive effect include:                
Warrant         70 70
Warrant [Member]                
Potential shares excluded from above weighted average share calculations due to their anti-dilutive effect include:                
Warrant 62         62
[1] Includes tax expense recorded in the amount of approximately $6,417,000 in the third quarter of 2024 in connection with a full valuation allowance against the Company’s U.S. deferred tax assets (see “Note 13 – Income Taxes” below for a discussion of this tax expense).